Takeda

To support women entrepreneurs in biotech, MassNextGen initiative launches

Monday, November 20, 2017

Takeda Pharmaceutical Company and the Massachusetts Life Sciences Center (MLSC) have formed a $1 million initiative aimed at supporting women entrepre­neurs in early-stage biotech with an eye toward addressing gender gaps in the life sciences sector. The five-year program, called the Massachu­setts Next Generation (MassNextGen) Initiative, provides funding and customized support, including mentoring from investors and industry executives, to empower women entrepreneurs and allow them to develop the network and skills necessary to become industry leaders.

[Read More]

Dixie-Lee Esseltine joins HBS Kraft Precision Medicine Accelerator

Friday, September 29, 2017

Dr. Dixie-Lee Esseltine, formerly the Vice President of Global Clinical Development at Takeda Pharmaceuticals, recently joined the Harvard Business School’s (HBS) Kraft Precision Medicine Accelerator. Esseltine will lead the Accelerator’s Clinical Trials work stream, which is comprised of leading nonprofit organizations (NPOs) and clinical leaders focused on precision medicine. The goal of this work stream is to accelerate the advancement of innovative platform trials across cancers by identifying best practices and sharing knowledge, helping NPOs build their understanding of the design and operation of master protocols, and working with the FDA to improve master protocols.

[Read More]

Takeda, Stanford University announce alliance

Thursday, August 17, 2017

Takeda Pharmaceutical has announced a collaboration with Stanford University to form the Stanford Alliance for Innovative Medicines (Stanford AIM), which will help transform novel Stanford research into next-generation treatments for diseases. Through this unique collaboration, Takeda and Stanford will identify projects on the path to therapeutic discoveries and accelerate the process of bringing these drugs to market to serve patients with unmet needs.

[Read More]

Takeda, Shattuck Labs partner on immuno-oncology

Monday, August 14, 2017

Takeda Pharmaceutical and Shattuck Labs have entered into a research collaboration to explore and develop checkpoint fusion proteins that have the potential to become highly differentiated, next-generation immunotherapies. Under the terms of the collaboration agreement, Takeda will hold options for exclusive global development and commercialization rights for up to four molecules resulting from the collaboration.

[Read More]

Takeda, Schrödinger form research collaboration

Friday, July 21, 2017

Takeda Pharmaceutical and Schrödinger, a privately held company dedicated to revolutionizing drug discovery through advanced computational methods, announced the formation of a multi-target research collaboration directed to diseases that align with Takeda’s core therapeutic areas of interest. The unique collaboration will combine Schrödinger’s in silico platform-driven drug discovery capabilities with Takeda’s deep therapeutic area knowledge and expertise in structural biology. With a focus on simplicity, speed and agility, Schrödinger will lead the multi-target discovery effort with Takeda providing protein crystal structures to aid Schrödinger in using its computational platform to guide the design of new chemical entities. Schrödinger will be responsible for its discovery costs.

[Read More]

Improved perception of the industry

Monday, June 12, 2017

The 2017 Global Pharmaceutical Reptrak study, prepared each year by Boston’s Reputation Institute, showed that the public’s perception of the pharmaceutical industry has improved, earning an industry score of 71.8, up from 68.2 in 2016. Furthermore, about 44% of respondents viewed the industry as having an excellent reputation, a seven point increase since 2016. Similarly, the number of respondents who perceived the industry as weak or poor declined, moving to 26% from 35% in 2016.

[Read More]

Takeda announces Takeda-PRA Development Center KK

Tuesday, April 11, 2017

Takeda Pharmaceutical has entered into an agreement for absorption-type company split with its wholly-owned subsidiary which was established in March 2017 (NewCo) and intends to enter into another agreement for joint venture with Pharm Research Associates (PRA(UK)), a subsidiary of PRA Health Sciences, aiming for transferring a part of Takeda Development Center Japan (TDC Japan) businesses to PRA. Takeda and PRA announced the expansion of their partnership to Japan on February 15, 2017.

[Read More]